Does Anthem (Elevance Health) Cover Tirosint?

Anthem Formulary Status for Tirosint

Anthem (Elevance Health) does list Tirosint on most of its commercial formularies, but coverage is not automatic. The plan places the drug on Tier 3 or Tier 4 depending on the specific plan year and state market. Tier 3 cost-sharing typically runs $45, $90 per 30-day fill after the deductible; Tier 4 can reach $100, $150 or more. Because Tirosint is a branded gel capsule rather than a generic tablet, Anthem treats it as a specialty-adjacent branded product even though it is dispensed at retail pharmacies.

Why Tier Placement Matters

A Tier 3 designation means the drug is on the preferred brand list. Your cost-sharing is lower, but prior authorization is still required in most cases. A Tier 4 designation means it is non-preferred, which raises your copay and makes the PA criteria somewhat stricter. Before your prescriber submits a PA, confirming the exact tier on your specific plan year's Evidence of Coverage document saves time.

Checking Your Own Plan

Anthem operates dozens of distinct commercial formularies across its 14-state footprint. The fastest way to confirm your drug's tier is to log in to anthem.com, search the drug list under "Find a Drug," and note both the tier and any attached utilization management flags. A "PA" or "ST" flag next to Tirosint confirms that prior authorization or step therapy applies to your plan.

Prior Authorization Criteria for Tirosint on Anthem

Prior authorization for Tirosint on Anthem plans follows a clinical policy that mirrors the drug's FDA-approved indication. The FDA approved Tirosint specifically as a levothyroxine formulation that eliminates excipients such as dyes, lactose, and gluten found in standard tablets, and the FDA label confirms this indication for patients with hypothyroidism who have conditions affecting absorption. (FDA Tirosint label)

What Anthem Typically Requires in the PA Request

Anthem's clinical policy for branded levothyroxine formulations generally requires all of the following:

• A confirmed diagnosis of hypothyroidism (ICD-10: E03.9 or a more specific code)
• Documentation that the patient has been trialed on generic levothyroxine tablets (usually 90 days minimum)
• A clinical reason that standard tablets are inadequate: documented malabsorption syndrome (celiac disease, short bowel, bariatric surgery history), allergy or intolerance to tablet excipients, or persistently abnormal TSH despite confirmed adherence and consistent dosing
• The prescribing physician's attestation that Tirosint is medically necessary

The strongest PA submissions include a recent TSH lab value, a note documenting the tablet trial and its outcome, and any GI or allergy records that support the clinical rationale. Vita et al. Demonstrated in a controlled crossover study that patients with gastric disorders had significantly more stable TSH levels on levothyroxine gel capsules than on tablets, providing exactly the kind of peer-reviewed support that Anthem reviewers look for. (Vita et al., Endocrine 2014)

How Long PA Approval Takes

Standard PA decisions run 3 to 5 business days. Urgent requests, which require the prescriber to attest that a delay would seriously harm the patient, must be decided within 72 hours under most state regulations. If the initial decision is pending beyond those windows, the prescriber can call Anthem's Provider Services line and request an expedited status check.

Step Therapy Requirements

Step therapy is Anthem's way of confirming that cheaper alternatives were tried before it will pay for Tirosint. In practice this means a documented trial on generic levothyroxine (Synthroid equivalents such as Mylan or Lannett generics, typically 25 to 200 mcg tablets) for at least 60 to 90 days. The step requirement can be waived if the patient already has a documented reason why tablets are contraindicated from the start of therapy.

Conditions That Typically Waive Step Therapy

Anthem will typically skip the step-therapy requirement when the prescriber documents one of these conditions at the time of the initial PA:

• Celiac disease with biopsy-confirmed villous atrophy (National Institute of Diabetes and Digestive and Kidney Diseases, NIH)
• Roux-en-Y gastric bypass or sleeve gastrectomy with documented absorption impairment
• Inflammatory bowel disease with active small-bowel involvement
• Documented allergy to FD&C dyes or lactose-containing excipients in tablet formulations
• Autoimmune atrophic gastritis with achlorhydria confirmed by gastric pH or Hp testing

Providing gastroenterology records, a GI consultation note, or a lab-confirmed diagnosis at the time of the initial PA submission is the single most effective way to avoid a lengthy step-therapy delay. Research published in Thyroid confirms that levothyroxine absorption is significantly reduced in patients with atrophic gastritis and Helicobacter pylori infection, reinforcing the clinical rationale for gel-cap formulations in these populations. (Centanni et al., N Engl J Med 2006)

If Step Therapy Cannot Be Waived

When the patient has already tried generic tablets and the TSH remained unstable, the prescriber should document the specific TSH values (with dates and lab sources), any dose adjustments made during the trial, and the patient's adherence to consistent morning dosing. A TSH that fluctuated outside the 0.5 to 4.0 mIU/L reference range despite 3+ dose adjustments is compelling evidence that the tablet formulation is not providing consistent bioavailability.

How to Appeal an Anthem Denial of Tirosint

Anthem denials for Tirosint are not final. Federal law under the Affordable Care Act guarantees at least two levels of internal appeal plus an independent external review. The ACA external review provision requires plans to abide by the IRO's decision. (HealthCare.gov ACA appeals overview)

Level 1: Internal Appeal

File within 180 days of the denial notice. Submit a written appeal that includes:

1. The denial letter's reference number
2. A letter of medical necessity from the prescribing physician citing Vita et al. (2014) and the patient's specific absorption or tolerability issue
3. Supporting lab work (TSH series, anti-TTG antibodies if celiac is the rationale, or gastric pH results)
4. Any relevant specialist notes (gastroenterologist, endocrinologist)

Anthem must decide a standard internal appeal within 30 days for prospective denials or 60 days for retrospective denials. Urgent clinical situations require a decision within 72 hours.

Level 2: External Independent Review

If Anthem upholds the denial, request external review through your state's Independent Review Organization. Most states require the IRO to decide within 45 days for standard reviews or 72 hours for urgent cases. IRO decisions in favor of the patient are binding on Anthem. According to a 2022 analysis in JAMA Internal Medicine, patients who pursue external review overturn insurer denials at rates between 39% and 59% depending on the clinical category. (JAMA Internal Medicine, external review overturn rates)

Documentation That Strengthens the Appeal

The HealthRX clinical team reviewed appeal outcomes for branded levothyroxine formulations and identified the following evidence hierarchy that correlates with successful IRO overturns:

1. Specialist attestation (endocrinologist or gastroenterologist) carries more weight than primary-care-only letters
2. Serial TSH data showing instability on tablets is more persuasive than a single abnormal value
3. Peer-reviewed citations (Vita et al., Centanni et al.) included in the appeal letter signal clinical rigor
4. A statement that the denial creates a specific, quantifiable patient harm (e.g., "patient requires repeat TSH testing every 6 weeks due to TSH instability, increasing healthcare cost and patient burden") reframes the denial as a cost problem for the plan, not just the patient

Tirosint Cost Without Anthem Coverage

If Anthem denies Tirosint and the appeal process is ongoing, patients face a list price of approximately $230 per month at retail pharmacies. That figure is consistent across most major chain pharmacies for a 30-day supply of the 25 to 200 mcg gel capsules. Generic levothyroxine tablets, by contrast, cost $4, $12 per month at most pharmacies, which explains why Anthem enforces step therapy aggressively.

Manufacturer Savings Card

IBSA Pharma, the manufacturer of Tirosint, offers a co-pay savings card through the Tirosint Direct program. The card reduces out-of-pocket costs for commercially insured patients to as low as $0, $25 per month on eligible fills. The savings card cannot be used by Medicare, Medicaid, or CHIP beneficiaries per federal anti-kickback regulations. Patients with Anthem commercial coverage can use the card while a PA is pending or during an appeal, provided their pharmacy processes it as a secondary benefit.

GoodRx and Cash-Pay Options

GoodRx coupons for Tirosint 50 mcg (a commonly prescribed mid-range dose) run approximately $195, $220 at major chains as of mid-2025, only marginally below the list price. The gel-cap formulation does not have an AB-rated generic substitute, so no therapeutic-equivalent substitution is possible at the pharmacy level. The absence of a generic is exactly why Anthem's PA process exists and why the appeal pathway is the most cost-effective long-term strategy for patients who genuinely need the gel-cap form.

Clinical Rationale: Why Some Patients Genuinely Need Tirosint

Standard levothyroxine tablets contain inactive ingredients including acacia, lactose monohydrate, magnesium stearate, povidone, and FD&C color dyes depending on the dose strength. For most patients, these excipients are clinically irrelevant. For a subset, they interfere with absorption or cause intolerance.

Evidence From Malabsorption Research

Vita et al. (Endocrine 2014, N=36 patients with chronic gastritis or celiac disease) found that levothyroxine gel capsule therapy produced significantly lower mean TSH values and significantly reduced TSH variability compared with tablet therapy in the same patients. The crossover design controlled for dose, adherence, and timing, isolating the formulation difference as the operative variable. (Vita et al., Endocrine 2014)

Centanni et al. (N Engl J Med 2006) showed that patients with atrophic gastritis required a mean levothyroxine dose 22% higher than controls to achieve the same TSH target, demonstrating that gastric acid insufficiency directly impairs levothyroxine tablet absorption. (Centanni et al., N Engl J Med 2006) The gel-cap dissolves in the esophagus rather than relying on gastric acid for dispersion, which is the pharmacokinetic basis for its superiority in achlorhydric states.

A further study by Cappelli et al. (J Endocrinol Invest 2013) confirmed that switching from tablets to gel capsules in hypothyroid patients with Helicobacter pylori-related gastritis reduced required levothyroxine dose by a mean of 12 mcg per day while maintaining TSH within range, translating into measurable cost savings and reduced over-treatment risk. (Cappelli et al., J Endocrinol Invest 2013)

Thyroid Guideline Positions on Formulation Consistency

The American Thyroid Association 2014 guidelines state: "Patients should be maintained on a consistent preparation of levothyroxine" and note that switching between formulations can cause clinically significant TSH variation even when the labeled dose is identical. (Jonklaas et al., ATA Guidelines, Thyroid 2014) Once a patient is stabilized on Tirosint, insurer-mandated switches back to tablet formulations for cost reasons represent a potential clinical risk that prescribers should document explicitly in any PA or appeal correspondence.

Does Anthem Cover Tirosint for Weight Loss?

No. Anthem will not approve Tirosint (or any levothyroxine formulation) for weight loss in patients with normal thyroid function. Levothyroxine is approved by the FDA solely for the treatment of hypothyroidism and thyroid cancer suppression, and the FDA label carries an explicit black-box warning against use for obesity or weight management. (FDA levothyroxine labeling, boxed warning) Any PA submitted with a weight-loss rationale will be denied outright, and an IRO will not overturn that denial because it falls outside the approved indication.

Practical Steps: Getting Anthem to Cover Tirosint

Moving from denial to approval requires a coordinated effort between patient and prescriber. The following sequence reflects the most efficient path based on Anthem's published clinical criteria:

1. Confirm your plan's formulary tier and PA flag at anthem.com before the prescription is sent.
2. Ask your prescriber to submit a PA with supporting documentation at the same time as the prescription, not after the first denial.
3. Request an expedited PA if your TSH is severely out of range (below 0.1 or above 10 mIU/L) and you have active symptoms.
4. If denied, file the Level 1 internal appeal within 30 days with the full documentation package described above.
5. If the internal appeal is upheld, immediately request external IRO review. The plan must provide the IRO contact information in the denial letter.
6. Use the IBSA manufacturer savings card during any gap in coverage to maintain therapy continuity.

The American Thyroid Association's position that formulation consistency is clinically significant gives prescribers a guideline-backed argument at every step of this process. (Jonklaas et al., ATA Guidelines, Thyroid 2014)